Healthcare Industry News: Conor Medsystems
News Release - February 1, 2007
Johnson & Johnson Completes Acquisition of Conor Medsystems, Inc.
NEW BRUNSWICK, N.J., Feb. 1 (HSMN NewsFeed) -- Johnson & Johnson (NYSE: JNJ ) today announced the closing of its previously announced acquisition of Conor Medsystems, Inc., a cardiovascular device company with a unique controlled drug delivery technology."The completion of the acquisition of Conor Medsystems adds an important platform to our capacity to address cardiovascular and vascular disease globally," said Nicholas J. Valeriani, Worldwide Chairman, Medical Devices and Diagnostics, Johnson & Johnson.
The Conor Medsystems CoStar® Stent* provides for drug elution from a cobalt chromium stent with a fully bioabsorbable polymer, and employs a unique site-specific drug delivery technology potentially applicable with other therapeutic agents in the treatment of other conditions.
"We look forward to exploring the potential for this novel reservoir technology in combination with other pharmaceutical agents and delivery systems as we seek new and better ways to address issues of cardiovascular and vascular disease," Valeriani concluded.
Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 200 Johnson & Johnson operating companies employ approximately 122,000 men and women and sell products throughout the world.
*The CoStar® Stent is not available for sale in the United States where it is an investigational device limited by law to investigational use.
Source: Johnson & Johnson
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
Related News Items
Johnson & Johnson MedTech Launches VOLT(TM) Plating SystemRYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
TALVEY(R) (talquetamab-tgvs) Demonstrates Highly Durable, Longer-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
